2026 CSGCT年会：从全球网络协作到中国临床落地，释放细胞与基因治疗转化新动能

Unleashing China's New Clinical and Regulatory Momentum to Accelerate Global CGT Translation

Chinese cell and gene therapy (CGT) sector is once again welcoming its annual top-tier event. From September 19 to 20, 2026, the 2026 Annual Meeting will be held at the Beijing Zhongguancun National Innovation Demonstration Zone Exhibition and Exchange Center. Under the theme "Unleashing China's New Clinical and Regulatory Momentum to Accelerate Global CGT Translation," the summit will feature a main forum, an international summit, and 23 sub-forums, covering the entire industry chain—including gene therapy, cell therapy, small nucleic acids, exosomes, tumor vaccines, AI, and CMC/CDMO.

The summit is guided by the Administrative Committee of Zhongguancun Science City, and co-hosted by Beijing Zhongguancun Science City Innovation Development Co., Ltd., the Beijing Haidian Zhongguancun Science City Jingke CGT Innovation Development Center, and the CSGCT China Cell and Gene Therapy Alliance. It is organized by Beijing Haixinyu Urban Renewal Group Co., Ltd., Beijing Haixing Technology Industry Service Co., Ltd., the HIEA Medical Innovation Ecosystem Alliance, and Arterial Network, with support from the Bank of China Beijing Haidian Sub-branch.

With broad attention from multiple stakeholders, this year's summit has attracted over 300 international participants, including leading scientists and experts in the global CGT field, alongside approximately 5,000 attendees from government, industry, academia, research, and medical sectors—spanning regulatory authorities, clinical institutions, pharmaceutical companies, biotech firms, CDMO/CRO providers, upstream supply chains, and investment institutions.

Beijing's pharmaceutical and health industry is accelerating its march toward becoming a globally influential, modern pharmaceutical and health industry cluster. In the CGT field, Haidian District boasts deep resource endowments, including 37 universities (including Peking University and Tsinghua University), 2 national laboratories, 26 national key laboratories in the pharmaceutical and health field, 96 national-level research institutions (represented by the Chinese Academy of Sciences), and 56 medical institutions at or above the secondary level. The deep convergence of high-caliber talent, clinical, and research resources provides the most solid foundational support for breakthroughs in new mechanisms and new processes in drug development.

In his address at the main forum, Lin Hang, Deputy District Mayor of Haidian District, Beijing, noted: "Haidian has precisely anchored itself to the CGT industry track. We have taken the lead in laying out functional cell drug R&D platforms such as TIL, Treg, and In Vivo CAR-T, and introduced a full-chain policy support system to drive innovative breakthroughs in the CGT industry. In Haidian, international innovation resources are rapidly converging, and local innovative enterprises are growing quickly. A virtuous cycle has taken shape—high-quality clinical resources attract deep collaboration with pharmaceutical companies, the industrial ecosystem is maturing, and the pace of innovative entities' landing is accelerating. Looking ahead, Haidian will continue to make the CGT industry a key frontier for focused development. We will keep optimizing the innovation ecosystem, and with the best services and the most complete ecosystem, work together with all of you to achieve new breakthroughs and development in the CGT industry."

Remarks by Lin Hang, Deputy District Governor of the Haidian District People's Government of Beijing

Liu Hui, Director of the Beijing Medical and Health Science and Technology Development Center, stated in her address: "Comparing the current development status of the CGT industry at home and abroad, Beijing stands out with strong innovation momentum, abundant clinical resources, and prominent advantages in segmented tracks. At the same time, to further implement Decree No. 818, the relevant municipal departments are jointly studying and advancing the implementation, ensuring a smooth connection between the rollout of the new policy and the high-quality development of the industry."

Liu Hui, director of the Beijing Center for the Development of Medical and Health Sciences, delivered a speech

01 Global collaboration  thought resonance

The International Summit on the morning of September 19 and the Main Forum on the morning of September 20 formed the intellectual high ground of the 2026 CSGCT Congress. 

The International Summit was themed “Gathering Momentum for Symbiosis—Global CGT Network Co-evolution and International Cooperation Forum,” while the Main Forum on the 20th was themed “Unleashing China’s New Clinical and Regulatory Momentum to Accelerate Global CGT Translation,” outlining a clear path for China’s CGT sector to integrate into the global innovation network. 

In March 2026, the CSGCT Alliance was officially established in Haidian. Wu Zhenhua, initiator and chairman of CSGCT and founder of JiaYin Biotech, delivered an address on how CSGCT helps accelerate global CGT translation. The CSGCT enables global resources to see China’s real clinical and industrial capabilities and brings business opportunities and cooperation to the entire Chinese CGT industry chain. To date, CSGCT has linked nine international CGT organizations; the Congress attracted more than 300 overseas participants; and it has reached 10,000 international CGT resources over the year.

CSGCT Founder, Chairman, Jianhua Wu, founder of Cain Biotechnology keynote speech

In addition, the Congress invited representatives from cell and gene therapy-related societies from Brazil, Canada, Australia, Asia, South Korea, and other countries and regions to attend. Witnessed by the attending delegates, the Beijing Initiative: Building a Global Gene and Cell Therapy Community was officially released. With five core principles—jointly building an open and inclusive international cooperation network, sharing the wisdom and outcomes of cutting-edge science and clinical translation, promoting the inclusive and accessible use of gene and cell medicines worldwide, jointly upholding ethical red lines and the trust cornerstone of industry development, and jointly charting the future resilience of technology and scientific endeavors—the Initiative carries the shared vision of CGT peers around the world.

The Beijing Initiative to Build a Global Community of Gene and Cell Therapy was officially launched

Meanwhile, participants jointly witnessed the milestone progress of the commercial launch of Northland’s Cedominji Injection. The product has been approved for the treatment of limb ulcers caused by severe lower limb ischemia (lower extremity arteriosclerosis obliterans, thromboangiitis obliterans, diabetic lower limb ischemia, etc.) in patients who are not suitable for revascularization surgery or for whom surgery is ineffective.

Northland Cedomicile Injection Commercialization The IPO officially launched

Jude Samulski, a Distinguished Professor at the University of North Carolina and a pioneer in gene therapy and AAV biology, delivered a keynote speech titled “Bench to Bedside, Lessons Learned: Next Round of Innovation.” He reviewed the arduous journey of gene therapy drugs from research and development to market approval. Taking the drug for spinal muscular atrophy (SMA) as an example, he noted that it took nearly nine years to be approved and has now been used in more than 5,500 children. The future challenges facing gene therapy are no longer technical issues, but how to pay for it and how to make it affordable for more patients.

Distinguished Professor at the University of North Carolina, Gene Therapy and AAV Pioneers in Biology Jude Samulski keynote speech

Claus Runge, Senior Vice President, Global Public Affairs, Sustainability and Internal Engagement, and Chief Health Equity Officer at Bayer, said that CGT faces challenges such as high complexity, high manufacturing costs, and an incomplete accessibility framework. No single institution can succeed alone; collaboration across science, regulation, industry, and capital is needed.

Senior Vice President, Bayer, Global Public Affairs, Sustainable Development and Internal Engagement and Chief Health Equity Officer Claus Runge keynote speech

Mark A. Kay, Professor of Pediatrics and Genetics at Stanford University and Director of the Human Gene Therapy Program, shared his team’s latest research on predicting AAV transduction efficiency and vector design. Interindividual epigenetic differences may lead to variability in dose response in clinical trials. In the future, it may be possible to modulate epigenetic states at the time of administration using small-molecule drugs, thereby reducing the required dose, lowering costs, and decreasing toxicity.

Professor of Pediatrics and Genetics at Stanford University and Director of Human Gene Therapy Mark A. Kay keynote speech

Wang Tao, Director of the Beijing Drug Regulatory Science Innovation Center, systematically outlined four core changes in CGT product regulation: clearer classification boundaries, accelerated approval, greater regulatory flexibility, and strengthened lifecycle management. He also revealed that guidelines on pharmaceutical changes, classification, and risk control will be issued in 2026, emphasizing that the regulatory system must match the high-risk and highly customized characteristics of CGT to form a closed loop.

Keynote speech by Wang Tao, director of the Beijing Center for Science and Innovation in Drug Regulatory Regulation

Xu Huji, Director of the Clinical Research Center, Director of the Department of Internal Medicine, and Director of the Department of Rheumatology and Immunology at the Second Affiliated Hospital of Naval Medical University (Changzheng Hospital), shared the opportunities and challenges of universal CAR-T and in vivo CAR-T in treating autoimmune diseases. In response to the pain points of autologous CAR-T, such as high cost and long turnaround time, off-the-shelf products derived from healthy donors have achieved certain efficacy in autoimmune and other diseases.

Director of the Clinical Research Center at the Second Hospital Affiliated to the Naval Medical University (Long March Hospital) Chief of General Internal Medicine and Chief of Rheumatology Xu Huji keynote speech

The roundtable discussion brought together diverse stakeholders from regulatory bodies, industry, and capital sectors, including the China Pharmaceutical Regulatory Research Association. CGT Wang Yue, Chairman of the Special Commission, took the overall direction of the new regulation policy; Founder, Chairman of Board of Directors, CEO, Chief Scientific Officer, CSGCT Co-chairs Li Zonghai, Xiao Xiao, co-founder, chairman and chief scientist of Belize Pharmaceuticals, Liao Cheng, founder and chairman of Rui Hendrie Pharmaceuticals and Yixiang Biotechnology CEO Mr. Ho et al. People in industry Bringing real-world insights into front-line clinical and commercial translation; Junfeng Wang, co-chief investment officer of Kingfisher Capital, took a capital perspective and discussed how to build a global economy powered by clinical resources and regulatory innovation. CGT The pipeline went down. “ China's Pivot Point ”。

Roundtable discussion

The international summit took place“Coming together - Global CGT Forum on the Collaborative Evolution of the Network and International Cooperation" The title first appeared.

Executive Director, Sovereign Capital, CSGCT Vice President of the League Qi Fei Brought the title: “ IN GLOBAL, FOR GLOBAL —— Building a Borderless Innovation Collaboration Network ” of theme The speech, the system comprises the world. CGT Industrial landscape, China's advantages, and CSGCT The value of a global collaboration platform.

Executive Director, Sovereign Capital, CSGCT Qi Fei, Vice President of the League, keynote speech

Many places around the world CGT The head of the academy showed up and talked. CGT The pattern of industry development. UMass Chan Professor of Medicine, ASGCT Former Chairman Guangping Gao share“ In Vivo Gene Therapy For Genetic Diseases ”，  Comb through it Spongiform white matter malnutrition gene therapy The research and development process and clinical translation results.

UMass Chan Professor of Medicine, ASGCT Former Chairman Guangping Gao keynote speech

ISCT Former Chairman Miguel Forte Call for global collaboration to accelerate product reach for patients. its An analysis of the current situation CGT The industry's challenges in market environment, financing, safety, clinical development and regulatory environment point to recent patient deaths as a reminder that the industry must carefully evaluate risk-to-benefit ratios and dosage exploration.

ISCT Former Chairman Miguel Forte keynote speech

uniQure Chief Commercial and Scientific Officer Richard Porter It brought Europe. AAV Leading companies in gene therapy have real-world experience. Asian cell therapy organizations （ Asian Cellular Therapy Organization ） Chairperson／President Akihiro Shimosaka Stressing, Cross-border clinical research must focus on quality and ethics, and calls for the establishment of a high-quality network of cross-border c trials in Asia.

uniQure Chief Commercial and Scientific Officer Richard Porter keynote speech

Asian cell therapy organizations （ Asian Cellular Therapy Organization ） Chairperson／President Akihiro Shimosaka keynote speech

President of the Brazilian Association for Cell and Gene Therapy Martin Bonamino I shared it. Current state of development of advanced therapies in Brazil ， Brazil is the first country in Latin America to introduce advanced therapies ( ATMPs ) Countries that have established regulatory frameworks, but Access to approved products in public health systems continues to face challenges Right now. Brazil is working for a new lease on life ATMP The times are ready, welcome Global Partners 。

President of the Brazilian Association for Cell and Gene Therapy Martin Bonamino keynote speech

Gene Therapy Canada Founder Ella Korets-Smith It was published under the title “Gene and Cell Therapy Ecosystem in Canada” The presentation shared with participants the experience of building the Canadian gene and cell therapy ecosystem, the strengths of rare disease populations, and international cooperation opportunities.

Gene Therapy Canada Founder Ella Korets-Smith keynote speech

02 Qianfan Racing at speed  The battle over therapies

In the In Vivo cell therapy track, the CSGCT Annual Meeting featured multiple specialized sessions that approached the field from three dimensions—viral vector delivery, non-viral vector delivery, and clinical research and full-lifecycle quality control—covering nearly all key nodes from bench to bedside.

I n Vivo Cell therapy-related subforums live

Virus vector routes What the practitioners were discussing? problem We've surpassed it. Delivery, but whether the drug can be developed after delivery and whether the risk can be controlled.

China Tongji Hospital, Affiliated with Tongji Medical School of China University of Science and Technology Division III Professor of Hematology / Dr. Chief Physician Li Chunrui shares In Vivo BCMA CAR-T Clinical progress in the treatment of recurrent refractory multiple myeloma. Chief Scientist of the Innovation Port of Concord 、 CSGCT Co-Chairs Zhang Dan, AAVivo Founder Haifeng Chen Bioscientific Medicine Founder Yang Lin, Jinfan Biology Director of Research and Development Pan gingi et al. revolved around chronic viral vector modification in vivo CAR-T Issues such as safety assessment were discussed.

The advantages of non-viral vector routes It is cheaper, faster to produce and repeatable to administer; The difficulty lies in expression persistence and target specificity.

Weizhen Biology, Sinopharm China National Biomedical Research Institute, Fosun Karyopharm BreezeBio Waiting for representatives share mRNA-LNP Targeting LNP 、 DNA payload Recent progress in such directions as non-viral delivery.

Meanwhile ， Gravel Biological Man and CEO 、 Microscopic creatures Initiation Person and CEO Liu Yarong, Boten Biotech Vice General Manager Chen Hui, Saifu Medicine Senior Vice President Dong Yansheng et al. from General Motors VS within the body CAR-T 、 tLNP vs LVV From the perspective of non-clinical evaluation, large-scale production, etc., outline In Vivo Drug pharmaceutical pathways for cell therapy.

Look together, A complete chain from vector to clinical, process to quality control gradually Take shape.

It's worth noting that in this case, Sinopharm China National Biotechnology Institute, Fosun Kary, Weizhen Biology, Shutong Technology 、 Promega The Species of the Rhine, the Only Species of Life etc. Under the witness of the representative The Global Times In Vivo The Cell Therapy Industry White Paper > The full text was released during the General Assembly. The White Paper was issued through He interviewed dozens of industry experts before and after, and conducted research in conjunction with visits. They have been disclosed. Data Completion Content Writing ， Around vector delivery, pharmaceutical pathways, and prospects for industrialization etc. Let's have an in-depth discussion.

The Global Report In Vivo The Cell Therapy Industry White Paper > Release Event

Another note that deserves attention of iPSC In the track, The congress was set up. iPSC Special Topic on Multi-directional Breakthrough Innovations, Chinese Academy of Medical Sciences Hospital of Hematology 、 Zhongsheng traces its origins 、 The Star-Eon creatures 、 Hawke's Creatures 、 Blood-derived organisms and others focused on the latest advances.

Participants Issues cover dual target areas CAR-iNK Save yourself from clinical exploration of disease, iPSC Clinical breakthroughs in derived cell therapy products, iPSC 2D and 3D Different processes development differences, iPSC treatment CNS Diseases, people iPSC Clinical development of neuroprecursor cell injections, iPSC Sources: platelet regeneration, etc.

Among them, Japan PMDA Review Director Yasuhiro Kishioka detailed Introduction to the latest regulatory framework for regenerative medicine products in Japan progress 。

In the field of gene editing, the Congress set up topics covering the full chain from basic tools to clinical translation. University of Michigan, USA Ann Arbor Sub-Principal appointed Associate Professor Yan Zhang, Yale University Professor, Department of Genetics and Institute of Systems Biology, School of Medicine Chansy, Stanford University Professor, Department of Bioengineering, Qi Lei ， Peking University Professor and founder of Boya Keen Wei Wensheng ， Qi Yuen Zoology Co-founder and CEO Kevin Zhao 、 Arbor Biotechnologies CSO Mathew Pletcher ， Bong Yao Biology Co-founder, Chief Scientist Du Bing ， This gene is a directing gene Founder Chui Yuga, wait. Just wait. CRISPR Base editing, epigenetic editing, small nucleic acid enzymes and recombinases, gene editing CAR-T Viruses VLP Lectures in vectors, in vivo gene editing therapy and other areas.

It is worth noting that clinical evidence for epigenetic and base editing is accumulating rapidly, and the drug boundaries of gene editing are expanding. Roundtable discussion “In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale” Event, representatives Discussion inside CRISPR Drugs go from scientific promise to realistic pathways for patients at scale.

For Positives Entering a critical period of industrialization Small nucleic acids and exosomal drugs, Assembly Forum Focus on delivery breakthroughs and industrialization ecology Deep communication.

RAB Biosciences Chairman and Chairman CEO Liang Zicai ， Shanghai Zhaowei Assistant President of Technology, Director of Technology Promotion Cai Kun ， Joycon Pharmaceuticals Head of research and development for oligonucleotide therapy Huang Zeo ， Yuji Creatures Co-founders Zhao Chengjiang Ling Tai krypton Initiation people Song Xu, The creatures of the day Vice President, Co-Founder Yang Wenbing ， Life in hot spots Vice President and Co-Founder of Yao Jing Genes Georgy. Yu Xiaohua, Vice General Manager of Synthese Genetics, Yunhe Pharmaceuticals Founder Zhu Yun We'll discuss chemical enzyme linking technology, double targeting. siRNA 、 ASO 、 AOC Extrahepatic delivery, AI drive RNA Issues such as monobase editing.

The topic of exosomes focuses on pharmaceutical innovation pathways. Liu Bicheng of Southeast University, Tao Yong of Chaoyang Hospital in Beijing, Yang Yijie of Integrated Biology, Gao Chunhong of National Standard Medicine, Zhang Hongwu of Sector, Zhao Libo of Enze Kangtai, Yang Yanlian of National Nanoscience Center, etc., from kidney disease to eye disease, iPSC The perspectives of exogenous sources, large-scale preparation, analytical characterization and quality control were explored.

In the tumour plate, the experts at the meeting around mRNA Cancer vaccines, DC Vaccines, new antigen prediction, AI Driving discussions on personalized targeting, commercial implementation, etc. Among them, LK-101 It is the first country to be allowed to enter the clinical stage. AI Drive personalized targeting mRNA Oncological vaccines have been approved for clinical use in China and the United States and completed hundreds of translational applications.

The speed of these technological routes has concrete industrial projections in Haidian. Zhongguancun Science City is Beijing CGT One of the industrial agglomerations, which has brought together a number of companies in In Vivo Cell therapy, iPSC Innovative companies that have worked in fields such as gene editing.

As of 2026 year 3 Data disclosed during the Zhongguancun Forum in May, Beijing is studying. CGT A significant proportion of the pipeline comes from Haidian. Authorities in Haidian district revealed that Beijing is in CGT Areas have formed an institutional layout: 20 One of Beijing's key laboratories, four concentrated areas, and a number of clusters CDMO platform 。

03 Compliance builds foundations and creates breakthroughs

The technological route determines how high CGT can soar, while CMC and CDMO determine whether it can land. 

On September 19, a sub-forum focusing on CMC quality systems and CDMO collaboration strategies was held, putting the thorniest manufacturing issues in CGT industrialization on the table—from full-lifecycle quality systems to the trade-off between cost and efficiency.

"From the beginning" IIT reach IND ， CMC and CDMO The Cost and Efficiency Game | Subforum Live

Zhao Moyuan, chairman of the Beijing Municipal Science and Technology Committee, pioneered the interpretation of "Several measures to support contract R & D production agencies for innovative drugs to improve quality and efficiency." ， Cincinnati Children's Applied Gene and Cell Therapy Center General Manager, Executive Director, Professor Chaozhong Zou share “From Bench to Commercial: CMC Quality & CDMO Partnerships in Cell & Gene Therapy” , the Advanced Therapy Center of the United States CMC and CDMO Lessons learned from cooperation are introduced Participants The field of view.

Hao Juanting, research value expert at Roche Diagnostic Products (Shanghai) Ltd., introduced Roche CGT Quality control solutions ， 2025 Liu Haijing, Chief Expert at the Shaanxi Institute for Drug Control and Chairperson of Part III of the Chinese Pharmacopoeia, presented on the construction of quality standard systems for innovative drugs and the progress in establishing standards for the Chinese Pharmacopoeia, reviewing the role of the Pharmacopoeia in... CGT The evolution of standards in the field 。

Around it CGT Process amplification, standardization and intelligence Believing Medicine, Jinfan Biosciences, Yuanqi Biosciences, Shenzhen Zhong Probe Cloud Intelligent Technology Co., Ltd. Representatives of companies such as Cain Biotechnology discussed From the lab to the lab GMP The path is.

Multiple Problems Step by step: CAR-T 、 MSC How are the core bottlenecks of gene editing and universal cell technologies different in process development? Small laboratory experiments GMP What parameters are most likely to get out of control during production transfer? CDMO How can we work with pharmaceutical companies to complete process locking and validation? How Automation Equipment Redefines CGT The craft? Where are the core technological breakthroughs for reducing the cost of scale production over the next three years?

In addition, the participants surrounded themselves. Total cycle management of quantitative compliance Engage in exchanges, Focus on emerging trends in regulatory policies, the establishment of routine tracking mechanisms under evolving regulations, the definition of critical quality attributes for live cell products, the latest developments in the Chinese Pharmacopoeia, and the challenges faced by small and medium-sized biopharmaceutical companies in building their own quality control systems. Wait for a topic 。

2017 After 2000, Beijing increased the supply of land elements for pilot and small-scale production, collecting and storing each year 400 Mounds of land were used for industrial space and a number of projects were supported CDMO Platforms, including artists Biology Self-built Shiseido Biotechnology and Taitech OpenCGT Wait. Zhongguancun Science City in Haidian CGT One of the industrial agglomerations is here. The plates are performing better and better. 。

Beijing in CDMO Aspect Systematic work has developed. Among them, The role of Haidian is particularly special. .. for example, Haidian is moving forward AI Capacity Injection CMC link 。

from IIT reach IND The technology of growth in the seabed ecology, for CGT Efficiency and Cost Boundaries in Manufacturing Bringing new change 。

At the same time, Evaluation of innovative methods ( NAMs ) Forum Focus CGT Human-related models and innovation evaluation systems in pharmaceuticals ， NAMs Could we really get in? CGT The path to drug discovery depends on whether the data is valuable, whether the validation is repeatable, and whether the regulatory communication mechanism is smooth. Guests, etc. Around organ-like chips, AI for 3D Biology Tumour-like organ validation pathways, NAMs Discussions were held on regulatory recognition, among other things.

04 Clinical Translations Global Fulcrum

Clinical translation and IIT further How to validate, how to comply with regulations, how to get patients to use it The question is.

“ China IIT Collaborating with clinical translation: healthcare companies work together to build a new global R & D footprint ”“ Clinical Translation and Global Development ： China's Practice and Internationalization Pathway in Gene Therapy ”Wait for a sub forum Topics, from policy interpretation, hospital support practice, pre-clinical program optimization, integration of medical research and production, and pediatric neurosurgery IIT Sharing perspectives such as the cross-cutting medical and worker aspects of brain tissue regeneration. CGT Practical experience in clinical translation.

Practitioners from different hospitals used their respective explorations to answer the same question: 818 After the command, IIT And how exactly clinical translation takes place.

Gao literature, director of the clinical research ward at the 10th People's Hospital in Shanghai, made a statement first. discuss Translational platforms from basic research to clinical research facilitate the implementation of new biomedical technologies. The clinical research ward is itself a translational platform, and how to smooth the discovery of basic research into clinical validation requires collaboration between the ward, the laboratory, ethics, and management.

Without supporting policies in the hospital, even good projects cannot be advanced. Jiangsu People's Hospital Clinical Medical Research Center, IIT Office leader Wang Yue shared hospital support practices ranging from stem cell clinical research to clinical translation of new biotechnologies.

Chen Cui Zhu, an assistant researcher at the National Major Scientific and Technological Infrastructure for Translational Medicine of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, has focused her perspective on in Optimizing the preclinical phase of cell and gene therapy regimens. How the pre-clinical protocol is designed and optimized directly determines the success or failure of subsequent clinical studies Beijing Union Hospital The translational medicine facility provides systematic support for such research. 。

The Department of Hematology at the General Hospital of the Chinese People's Liberation Army has accumulated profound expertise in the field of cell therapy. ， Deputy Chief Physician Ma Chao from the Department of Hematology at the General Hospital of the Chinese People's Liberation Army introduced the integrated medical research, development, and production platform for cell and gene therapy translation. .. The multi-center joint practice led by the Ministry of Health attempts to break down barriers between medical, research and production.

Wu Xinfeng, Secretary of the Office of Clinical Research Management at Xuanwu Hospital, Affiliated with Capital Medical University 、 Zhang Wei, associate physician in neurosurgery at Beijing Children's Hospital, affiliated with Capital Medical University 、 Su Wei, deputy director of neurosurgery at Tsinghua Chang'e Hospital in Beijing 、 Zhang Nina, associate director of the clinical research management center at Zhulou Hospital, affiliated with Nanjing University Each brings years of exploration experience.

Experience from the front line is exactly what it is. 818 Orders move from institutions to the most needed reference in practice.

Haidian's clinical resources have irreplaceable advantages in this process. ， A number of top medical institutions are located here, CSGCT The alliance has connected overseas project parties to Haidian. many A hospital is being opened. IIT 。

In addition, the conference has organized a dedicated project pitch session and arranged for Chinese IIT Resource exchanges, CGT overseas BD Resource-exchange meetings and hospital-to-company meetings have established direct communication channels for innovative enterprises and clinical institutions, investment institutions and multinational pharmaceutical companies.

The future, CSGCT We will continue to build an open, authoritative, and efficient global dialogue mechanism to enable China's cell and gene therapy industry to deeply engage in global innovation and standard-setting, contributing Chinese wisdom and solutions to the advancement of human health.